Reading ACRV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACRV free→Reading ACRV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACRV free→QuarterlyIQ Insights · ACRV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 13, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2026, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the…
and Item 7.01, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.
Termination of Material Definitive Agreement On February 18, 2026, Acrivon Therapeutics, Inc. (the “Company”) announced the completion and certification of its internally, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA) certified laboratory, located on premises in Watertown, Massachusetts. With these in-house capabilities, on February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into…
Results of Operations and Financial Condition. On January 8, 2026, Acrivon Therapeutics, Inc. (the “Company”) disclosed that, based on preliminary unaudited financial information, it had preliminary unaudited cash, cash equivalents, and investments of approximately $119 million as of December 31, 2025, which, based on current operating plans, is expected to fund operations into the second quarter of 2027. Because the Company’s consolidated financial statements for the year ended December 31,…
Other Events On January 8, 2026, the Company announced the following clinical data: ACR-368: Potential First-in-Class CHK1 / CHK2 Inhibitor • In Arm 1 of the ACR-368 Phase 2b registrational-intent trial (monotherapy BM+ subjects) an updated interim analysis (EDC data extract as of December 4, 2025) showed a ORR of 39%*. In subjects with ≤2 prior lines of therapy (LoT), the ORR was 44%. Based on data that showed higher response rates in subjects with serous EC (also called uterine serous carci…
Results of Operations and Financial Condition. On November 13, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section…
Results of Operations and Financial Condition. On August 13, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended June 30, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of t…
Results of Operations and Financial Condition. On May 14, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the…
Results of Operations and Financial Condition. On March 25, 2025, Acrivon Therapeutics, Inc. (the “Company”) disclosed a preliminary cash and cash equivalents and short-term investments balance of approximately $184.6 million as of December 31, 2024. Because the Company’s consolidated financial statements for the twelve months ended December 31, 2024 have not yet been finalized, the preliminary statement of the Company’s cash and cash equivalents and short-term investments as of December 31,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.